Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220405 | 1.00 | POLB (0.38) | POLBGAACHRM2CHRM1KMT2A | |
| SCHEMBL24145355 | 1.00 | POLB (0.38) | POLBGAACHRM2CHRM1KMT2A | |
| SCHEMBL17928956 | 1.00 | POLB (0.38) | POLBGAACHRM2CHRM1KMT2A | |
| SCHEMBL20329541 | 1.00 | POLB (0.38) | POLBGAACHRM2CHRM1KMT2A | |
| SCHEMBL10440862 | 0.88 | CHRM2 (0.42) | POLBGAACHRM2CHRM1KMT2A | |
| SCHEMBL30454878 | 0.88 | POLB (0.35) | POLBGAACHRM2CHRM1KMT2A | |
| SCHEMBL29189673 | 0.82 | CHRM2 (0.38) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL14627937 | 0.82 | CHRM2 (0.38) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL24752585 | 0.82 | CHRM2 (0.38) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL29189672 | 0.82 | CHRM2 (0.38) | CHRM2CHRM1KMT2AMEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | REATA PHARMACEUTICALS, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230132332-A1 | Green Methods of Carbohydrate Acetylation | UNITED STATES DEPARTMENT OF ENERGY | 2023-04-27 | — | — | US | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1358183-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| WO-2002088106-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132332-A1 | Green Methods of Carbohydrate Acetylation | PUF60, HDAC10, NAT10 | POLB 2890/4885GAA 1174/4885CHRM2 2309/4885 |
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | POLB 4412/4885GAA 834/4885CHRM2 2622/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | POLB 4505/4885GAA 813/4885CHRM2 2809/4885 |
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | POLB 3719/4885GAA 1039/4885CHRM2 2529/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | POLB 4674/4885GAA 1175/4885CHRM2 2949/4885 |
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | POLB 3719/4885GAA 1039/4885CHRM2 2529/4885 |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | HSPA2, HSP90AB2P, HSF1 | POLB 3229/4885GAA 315/4885CHRM2 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.